From T-cell collection to CAR T-cell infusion

Myeloma Patients Europe (MPE) has conducted four written interviews on CAR-T manufacturing to better understand various myeloma CAR-T therapies’ manufacturing processes and challenges. Four stakeholders have answered our questions, including two pharmaceutical companies, each with a myeloma CAR-T product approved in the European Union, and two academic teams which have developed myeloma CAR-T products currently under clinical investigation.

• Interview of Janssen Pharmaceuticals on their CAR T-cell manufacturing process

• Interview of  Prof. Dr. Bönig, Goethe University, Frankfurt, Germany, on their CAR T-cell manufacturing process

• Interview of Hadassah Hebrew University Centre, Jerusalem, Israel, on their CAR T-cell manufacturing process

• Interview of Bristol Myers Squibb (BMS) on their CAR T-cell manufacturing process

You can also explore the MPE CAR-T resource page on the website here.